Abstract
Cholesteryl ester transfer protein (CETP) facilitates movement of esterified cholesterol between high-density lipoproteins (HDLs) and apolipoprotein B-containing lipoproteins. By virtue of their ability to raise HDL cholesterol and lower low-density lipoprotein cholesterol, pharmacological inhibitors of CETP have received considerable attention as potential new agents in cardiovascular prevention. While early studies of CETP inhibitors have demonstrated a lack of clinical efficacy and potential toxicity, development of the potent CETP inhibitor, anacetrapib, has moved forward, with emerging evidence suggesting a role in reducing cardiovascular events. The experience with anacetrapib and its potential for use in clinical practice are reviewed here.
Original language | English |
---|---|
Pages (from-to) | 3497-3502 |
Number of pages | 6 |
Journal | Drug Design, Development and Therapy |
Volume | 11 |
DOIs | |
Publication status | Published or Issued - 7 Dec 2017 |
Keywords
- Anacetrapib
- Atherosclerosis
- CETP
- Cardiovascular disease
- Lipids
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science
- Drug Discovery